Jack Nielsen Net Worth

The estimated Net Worth of Jack Nielsen is at least $540 Million dollars as of 14 December 2022. Mr. Nielsen owns over 2,834 units of Reata Pharmaceuticals Inc stock worth over $443,141,697 and over the last 8 years he sold RETA stock worth over $96,515,535. In addition, he makes $611,774 as Independent Director at Reata Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Nielsen RETA stock SEC Form 4 insiders trading

Jack has made over 26 trades of the Reata Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 2,834 units of RETA stock worth $169,927 on 14 December 2022.

The largest trade he's ever made was selling 300,741 units of Reata Pharmaceuticals Inc stock on 5 July 2022 worth over $16,658,044. On average, Jack trades about 41,323 units every 52 days since 2016. As of 14 December 2022 he still owns at least 2,571,024 units of Reata Pharmaceuticals Inc stock.

You can see the complete history of Mr. Nielsen stock trades at the bottom of the page.

Jack Nielsen biography

Jack B. Nielsen serves as Independent Director of the Company. Mr. Nielsen is a Managing Director in Vivo Capital, LLC, a healthcare focused investment firm. Prior to March 1, 2017, Mr. Nielsen worked within the Novo A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012, Mr. Nielsen was employed as a Partner at Novo Ventures (US) Inc. in San Francisco, where he established the office which provides certain consultancy services to Novo A/S. He currently serves on the board of directors of Crinetics Pharmaceuticals, Inc., a publicly-traded company. Mr. Nielsen in the past has served on the board of directors of Akebia Therapeutics, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is a publicly-traded company. He is also currently a member of the board of directors of a number of private companies. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark, and a Masters in Management of Technology from Center for Technology, Economics and Management, Technical University of Denmark. Our Board believes that Mr. Nielsen is qualified to serve on our Board due to his extensive industry experience, his experience with venture capital investments and his board service for several companies in the biotechnology sector.

What is the salary of Jack Nielsen?

As the Independent Director of Reata Pharmaceuticals Inc, the total compensation of Jack Nielsen at Reata Pharmaceuticals Inc is $611,774. There are 10 executives at Reata Pharmaceuticals Inc getting paid more, with Manmeet Soni having the highest compensation of $12,612,200.

How old is Jack Nielsen?

Jack Nielsen is 56, he's been the Independent Director of Reata Pharmaceuticals Inc since 2006. There are 6 older and 9 younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.

Insiders trading at Reata Pharmaceuticals Inc

Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy, and Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.

What does Reata Pharmaceuticals Inc do?

reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Complete history of Mr. Nielsen stock trades at Reata Pharmaceuticals Inc, Crinetics Pharmaceuticals Inc, Harmony Biosciences, Aligos Therapeutics, and ALX Oncology

Reata Pharmaceuticals Inc executives and stock owners

Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Manmeet Soni,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President
• J. Warren Huff,
  Chairman of the Board, President, Chief Executive Officer
• Colin Meyer,
  Executive Vice President, Chief Research and Development Officer
• Michael Wortley,
  Executive Vice President, Chief Legal Officer
• Dawn Bir,
  Executive Vice President, Chief Commercial Officer
• Manmeet Singh Soni,
  COO, CFO & Pres
• J. Warren Huff,
  Chairman & CEO
• Dr. Colin J. Meyer M.D.,
  Exec. VP & Chief Innovation Officer
• Michael D. Wortley,
  Exec. VP & Chief Legal Officer
• Dawn Carter Bir,
  Exec. VP & Chief Commercial Officer
• Jack Nielsen,
  Independent Director
• William McClellan,
  Independent Director
• William Rose,
  Independent Director
• R. Kent McGaughy,
  Independent Director
• Vineet Jindal,
  Vice President, Corporate Communications and Strategy
• Martin Edwards,
  Independent Director
• Seemi Khan,
  Chief Medical Officer
• Andrea Loewen,
  Vice President - Global Regulatory Affairs
• Kevin Johnston,
  Chief Technical Officer, Vice President
• Steve Harman,
  VP & Chief HR Officer
• Dakota Gallivan,
  VP & Chief Healthcare Compliance Officer
• Dr. W. Christian Wigley Ph.D.,
  Sr. VP & Chief Scientific Officer
• Bhaskar Anand,
  VP & Chief Accounting Officer
• William Puffin Partners, L....,
  
• Dennis K. Stone,
  Director
• Elaine Castellanos,
  VP, Chief Accounting Officer
• Holdings A/S Novo,
  10% owner
• James Edward Bass,
  Director
• James W Jr Traweek,
  
• Inc Cpmg,
  
• Inc. Abb Vie,
  10% owner
• Keith Wayne Ward,
  See Remarks
• William Rose Evelyn P.Edwar...,
  
• William Puffin Partners, L....,
  
• Antal Rohit Cpmg Inc Desai,
  
• William Montrose Investment...,
  
• William Charles Henry Rose ...,
  
• William Puffin Partners, L....,
  
• William Estate Of Edward W....,
  
• Jason Douglas Wilson,
  Executive VP of Operations
• Pharma Llcstapleton Craig R...,
  
• Christy J. Oliger,
  Director
• Shamim Ruff,
  Director
• Bhaskar Anand,
  SVP, Chief Accounting Officer
• Steven Ryder,
  Director
• Samina Khan,
  SVP, Chief Medical Officer
• Rajiv Patni,
  EVP, Chief R&D Officer